About Rezolute
Rezolute is a company based in Denver (United States) founded in 2012 by Nevan Charles Elam and Hoyoung Huh.. The company has 59 employees as of June 30, 2024. Rezolute offers products and services including Ersodetug. Rezolute operates in a competitive market with competitors including Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others.
- Headquarter Denver, United States
- Employees 59 as on 30 Jun, 2024
- Founders Nevan Charles Elam, Hoyoung Huh
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Rezolute, Inc.
-
Annual Revenue
$00as on Jun 30, 2024
-
Net Profit
$-68.46 M-32.19as on Jun 30, 2024
-
EBITDA
$-70.39 M-26.58as on Jun 30, 2024
-
Latest Funding Round
$41 M (USD), Post-IPO
Oct 09, 2020
-
Investors
Citadel
& 6 more
-
Employee Count
59
as on Jun 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Rezolute
Rezolute is a publicly listed company on the NASDAQ with ticker symbol RZLT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Rezolute
Rezolute offers a comprehensive portfolio of products and services, including Ersodetug. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug for treating congenital hyperinsulinism in clinical trials
Unlock access to complete
Unlock access to complete
Funding Insights of Rezolute
- Total Funding Total Funding
- Total Rounds 25
- Last Round Post-IPO — $41.0M
-
First Round
First Round
(07 Aug 2012)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Post-IPO - Rezolute | Valuation |
investors |
|
| Jul, 2019 | Amount | Post-IPO - Rezolute | Valuation |
investors |
|
| Apr, 2018 | Amount | Post-IPO - Rezolute | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Rezolute
Rezolute has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Citadel, Handok and Genexine. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location | |
|
Private equity investments are directed toward North American opportunities.
|
Founded Year | Domain | Location | |
|
Investment firm managing opportunistic strategies in equity and credit markets.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Rezolute
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Rezolute
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Rezolute Comparisons
Competitors of Rezolute
Rezolute operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Rezolute
Frequently Asked Questions about Rezolute
When was Rezolute founded?
Rezolute was founded in 2012.
Where is Rezolute located?
Rezolute is headquartered in Denver, United States. It is registered at Denver, Colorado, United States.
Who is the current CEO of Rezolute?
Nevan Charles Elam is the current CEO of Rezolute. They have also founded this company.
How many employees does Rezolute have?
As of Jun 30, 2024, the latest employee count at Rezolute is 59.
What does Rezolute do?
Rezolute (formerly Antriabio) is a biopharmaceutical company, developing drugs for metabolic and orphan diseases. The lead candidate, RZ358 is an insulin receptor antagonist monoclonal antibody for congenital hyperinsulinism (CHI), has an orphan drug designation(Phase 2). Another molecule, AB101 is a once-weekly injectable basal insulin for diabetes management (in Phase 1). Also developing plasma kallikrein inhibitors (PKI) for diabetic macular edema (DME) hereditary angioedema (HAE). In Dec 2017, the company had entered into a license agreement with Xoma which gives Rezolute exclusive global rights to develop and commercialize RZ358, formerly called XOMA 358.
Who are the top competitors of Rezolute?
Rezolute's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Rezolute offer?
Rezolute offers Ersodetug.
Is Rezolute publicly traded?
Yes, Rezolute is publicly traded on NASDAQ under the ticker symbol RZLT.
Who are Rezolute's investors?
Rezolute has 7 investors. Key investors include Citadel, Handok, Genexine, CAM Capital, and Federated Hermes.
What is Rezolute's ticker symbol?
The ticker symbol of Rezolute is RZLT on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.